Macular degeneration trials in Austria

In Austria 16 Also abroad 218

16 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD
Where
Innsbruck, Linz, Mistelbach
Age
50 years and over
People
250 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06847542 · EU 2024-516924-32-00
Phase 3Taking people
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Where
Graz, Vienna
Age
50 years to 85 years
People
975 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT06541704 · EU 2023-509547-27-00
Phase 3Taking people
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
Where
Graz, Innsbruck, Linz, Mistelbach, Salzburg
Age
50 years and over
People
561 worldwide
Run by
AbbVie
See details and how to joinNCT07007065 · EU 2024-512298-28-00
Phase 3Taking people
Extension Study for the Port Delivery System With Ranibizumab (Portal)
Where
Graz, Vienna
Age
50 years and over
People
1,000 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT03683251 · EU 2023-507131-38-00
Phase 2/3Taking people
A clinical trial of EYE201/MK-8748 in people with macular degeneration (MK-8748-003)
Where
Graz, Innsbruck, Vienna
Age
18 years and over
People
250 worldwide
Run by
Eyebiotech Limited
See details and how to join2025-524894-17-00 · EU 2025-524894-17-00
Phase 2Taking people
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
Where
Linz, Vienna
Age
55 years and over
People
324 worldwide
Run by
ONL Therapeutics
See details and how to joinNCT06659445 · EU 2024-513174-22-00
Phase 2Taking people
Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
Where
Graz, Innsbruck, Vienna
Age
60 years and over
People
240 worldwide
Run by
ADARx Pharmaceuticals, Inc.
See details and how to joinNCT06990269 · EU 2025-521779-30-00
No phaseTaking people
Stem Cell Ophthalmology Treatment Study II
Where
Vienna
Age
18 years and over
People
500 worldwide
Run by
MD Stem Cells
See details and how to joinNCT03011541
Phase 4Taking people
Two initial aflibercept 8 mg loading doses in treatment-naive neovascular AMD
Where
Graz
Age
18 years and over
People
50
Run by
Medical University Of Graz
See details and how to join2025-523478-17-00 · EU 2025-523478-17-00
No phaseTaking people
Retinal Photoreceptor Outer Segment Length Before and After Light Stimulation - a Pilot Study
Where
Vienna
Age
18 years and over
People
35
Run by
Medical University of Vienna
See details and how to joinNCT03921931
No phaseTaking people
Personalized Monitoring of Non-foveal, Non-vision Compromising Atrophic Age-related Macular Degeneration With Artificial Intelligence and Identification of Disease Progression
Where
Vienna
Age
55 years to 99 years
People
200 worldwide
Run by
Medical University of Vienna
See details and how to joinNCT06351657
No phaseTaking people
Personalised Monitoring of Early and Intermediate Age-related Macular Degeneration With Artificial Intelligence and Identification of Disease Progression
Where
Vienna
Age
55 years to 99 years
People
500 worldwide
Run by
Medical University of Vienna
See details and how to joinNCT06351670
No phaseTaking people
Aflibercept in Recurrent or Persistent CNV
Where
Vienna
Age
50 years and over
People
80
Run by
Medical University of Vienna
See details and how to joinNCT02669953
Phase 4Taking people
Treatment of Neovascular AMD: Artificial Intelligence in Real-world Setting
Where
Vienna
Age
50 years to 100 years
People
290
Run by
Medical University of Vienna
See details and how to joinNCT05093374
No phaseEnrolling by invitation
Deciphering AMD by Deep Phenotyping and Machine Learning- Prospective Study - SUMMIT (Part 2)
Where
Vienna
People
300 worldwide
Run by
University of Southampton
See details and how to joinNCT06682455
No phaseTaking people
Diagnostic Possibilities in Ophthalmological Diseases Using Swept Source Optical Coherence Tomography
Where
Linz
Age
5 years to 110 years
People
500
Run by
Johannes Kepler University of Linz
See details and how to joinNCT06074731